Table 2.
Model estimates after applying each analytical method to SAH patients to determine the association between vasopressor and mortality within the EHR dataset. Outcome models (with the exception of the unadjusted model) adjusted for age at baseline, gender, race, and marital status.
| Analytical Method | Dopamine vs Phenylephrine | Norepinephrine vs Phenylephrine | Dopamine vs Norepinephrine | |||
|---|---|---|---|---|---|---|
| OR [95% CI] | p-value | OR [95% CI] | p-value | OR [95% CI] | p-value | |
| Unadjusted | 3.06 [2.46–3.81] | <0.001 | 2.53 [2.08–3.09] | <0.001 | 1.21 [0.96–1.53] | 0.110 |
| Adjusted | 3.02 [2.42–3.76] | <0.001 | 2.63 [2.15–3.22] | <0.001 | 1.15 [0.91–1.45] | 0.253 |
| GBM Weighted | 2.19 [1.70–2.81] | <0.001 | 2.24 [1.80–2.80] | <0.001 | 0.97 [0.75–1.27] | 0.852 |
| GPS-CDF Greedy Matched | 1.53 [1.11–2.10] | 0.008 | 1.41 [1.00–1.99] | 0.051 | 1.09 [0.79–1.49] | 0.610 |
| GPS-CDF Stratification | 2.59 [2.03–3.31] | <0.001 | 3.21 [2.55–3.31] | <0.001 | 0.81 [0.61–1.07] | 0.138 |